(Total Views: 770)
Posted On: 02/08/2025 1:26:03 PM
Post# of 150022
GF/ViiV(GSK) buys our HIV for a few billion cash.
Cytodyn disperses 100% to shareholders, as a 1 time, Special Dividend thank you to shareholders.
Non-toxic Patents, Hiv data, FcRn, Cure potential, 1600 patient safety/data, Abstracts, press releases, Cytodyn & 3rd party funded trials, now gives Cytodyn a rock solid foundation.
Keep in mind, ViiV(GSK) owns one of our Hiv FcRn mutations.
Because of all this, GSK "buys" Cytodyn by rolling 100% of our shares into GSK.
GSK's only cost to owning Cytodyn is our 1.2b shares.
Answers the question of "who can afford to buy us".
Because "$10b,$40b,$60b,$100b" is then not needed from GSK for all of Cytodyn.
We still benefit 100% from Leronlimab, through a fully verticaly integrated, GSK.
GSK keeps rights to prefered indications.
Liscence/royalty agreements on others.
Dr. J joins GSK for few years due to the indications.
Dr. Lataillade stays @ GF post GSK/Cytodyn work.
Dr. Sacha @ GF/ViiV(GSK) in an Hiv Exec capacity.
I posted most of this Oct. 2024.
Today's world events, to me, this would really be àttractive now to a GSK for many reasons.
A "1 & done" transaction to owning Cytodyn.
Making anyone short Cytodyn, needing to cover @ GSK's share price.
Massive upward squeeze on our GSK shares.
..
Cytodyn disperses 100% to shareholders, as a 1 time, Special Dividend thank you to shareholders.
Non-toxic Patents, Hiv data, FcRn, Cure potential, 1600 patient safety/data, Abstracts, press releases, Cytodyn & 3rd party funded trials, now gives Cytodyn a rock solid foundation.
Keep in mind, ViiV(GSK) owns one of our Hiv FcRn mutations.
Because of all this, GSK "buys" Cytodyn by rolling 100% of our shares into GSK.
GSK's only cost to owning Cytodyn is our 1.2b shares.
Answers the question of "who can afford to buy us".
Because "$10b,$40b,$60b,$100b" is then not needed from GSK for all of Cytodyn.
We still benefit 100% from Leronlimab, through a fully verticaly integrated, GSK.
GSK keeps rights to prefered indications.
Liscence/royalty agreements on others.
Dr. J joins GSK for few years due to the indications.
Dr. Lataillade stays @ GF post GSK/Cytodyn work.
Dr. Sacha @ GF/ViiV(GSK) in an Hiv Exec capacity.
I posted most of this Oct. 2024.
Today's world events, to me, this would really be àttractive now to a GSK for many reasons.
A "1 & done" transaction to owning Cytodyn.
Making anyone short Cytodyn, needing to cover @ GSK's share price.
Massive upward squeeze on our GSK shares.
..
(5)
(1)Scroll down for more posts ▼
